For example, the TLR7 and TLR9 agonists are used to treat skin cancer and cutaneous T-cell lymphoma (reviewed in [12]), and TLR9 agonists are being tested in clinical trials against NSCLC [13]. This evidence concerns the gene TLR9 and primary cutaneous T-cell non-Hodgkin lymphoma.